JP2017532959A5 - - Google Patents

Download PDF

Info

Publication number
JP2017532959A5
JP2017532959A5 JP2017519013A JP2017519013A JP2017532959A5 JP 2017532959 A5 JP2017532959 A5 JP 2017532959A5 JP 2017519013 A JP2017519013 A JP 2017519013A JP 2017519013 A JP2017519013 A JP 2017519013A JP 2017532959 A5 JP2017532959 A5 JP 2017532959A5
Authority
JP
Japan
Prior art keywords
subject
gene
threshold
mdm2i
score
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2017519013A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017532959A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2015/079389 external-priority patent/WO2016056673A1/en
Publication of JP2017532959A publication Critical patent/JP2017532959A/ja
Publication of JP2017532959A5 publication Critical patent/JP2017532959A5/ja
Withdrawn legal-status Critical Current

Links

JP2017519013A 2014-10-09 2015-10-09 Mdm2阻害剤に対する感受性の遺伝子シグネチャーに基づく予測因子に関するアルゴリズム Withdrawn JP2017532959A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462061992P 2014-10-09 2014-10-09
US62/061,992 2014-10-09
PCT/JP2015/079389 WO2016056673A1 (en) 2014-10-09 2015-10-09 Algorithms for gene signature-based predictor of sensitivity to mdm2 inhibitors

Publications (2)

Publication Number Publication Date
JP2017532959A JP2017532959A (ja) 2017-11-09
JP2017532959A5 true JP2017532959A5 (show.php) 2018-11-22

Family

ID=54396934

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017519013A Withdrawn JP2017532959A (ja) 2014-10-09 2015-10-09 Mdm2阻害剤に対する感受性の遺伝子シグネチャーに基づく予測因子に関するアルゴリズム

Country Status (4)

Country Link
US (1) US20170283885A1 (show.php)
EP (1) EP3204514A1 (show.php)
JP (1) JP2017532959A (show.php)
WO (1) WO2016056673A1 (show.php)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2508531B1 (en) 2007-03-28 2016-10-19 President and Fellows of Harvard College Stitched polypeptides
KR20140100937A (ko) 2011-10-18 2014-08-18 에일러론 테라퓨틱스 인코포레이티드 펩티도미메틱 거대고리
JP6450192B2 (ja) 2012-02-15 2019-01-09 エイルロン セラピューティクス,インコーポレイテッド トリアゾール架橋した、およびチオエーテル架橋したペプチドミメティック大環状化合物
WO2014071241A1 (en) 2012-11-01 2014-05-08 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
CA2961029A1 (en) 2014-09-24 2016-03-31 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and formulations thereof
SG11201702223UA (en) 2014-09-24 2017-04-27 Aileron Therapeutics Inc Peptidomimetic macrocycles and uses thereof
US10253067B2 (en) 2015-03-20 2019-04-09 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
GB201517216D0 (en) 2015-09-29 2015-11-11 Cancer Res Technology Ltd And Astex Therapeutics Ltd Pharmaceutical compounds
GB201517217D0 (en) 2015-09-29 2015-11-11 Astex Therapeutics Ltd And Cancer Res Technology Ltd Pharmaceutical compounds
KR20190068544A (ko) * 2016-10-17 2019-06-18 다이이찌 산쿄 가부시키가이샤 Mdm2 저해제와 dna 메틸트랜스페라아제 저해제의 병용 치료법
CN107974502B (zh) * 2016-10-19 2021-07-02 北京大学人民医院 一种用于同时检测nbpf10、tsfm、prb2及diaph1基因突变的试剂盒
GB201704965D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
GB201704966D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
RU2747746C2 (ru) * 2018-10-24 2021-05-13 Общество с ограниченной ответственностью «Онкобокс» Тест-классификатор клинического ответа на лечение сорафенибом индивидуальных пациентов с раком почки
GB201919219D0 (en) 2019-12-23 2020-02-05 Otsuka Pharma Co Ltd Cancer biomarkers
WO2021228814A1 (en) * 2020-05-15 2021-11-18 ETH Zürich Mdm2 inhibitor response prediction method
GB202103080D0 (en) 2021-03-04 2021-04-21 Otsuka Pharma Co Ltd Cancer biomarkers
US20240336972A1 (en) * 2021-07-30 2024-10-10 Oregon Health & Science University Methods for selecting melanoma patients for therapy and methods of reducing or preventing melanoma metastasis
CN118398086B (zh) * 2024-04-19 2026-01-06 山东云海国创云计算装备产业创新中心有限公司 抗癌药物反应预测方法、装置、计算机设备及存储介质

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20140409T1 (hr) * 2009-01-16 2014-06-06 Daiichi Sankyo Company, Limited Derivat imidazola sa strukturom prolinskog prstena
WO2012121361A1 (ja) * 2011-03-10 2012-09-13 第一三共株式会社 ジスピロピロリジン誘導体
US20120328692A1 (en) * 2011-06-24 2012-12-27 University Of Maryland, Baltimore Potent d-peptide antagonists of mdm2 and mdmx for anticancer therapy
WO2014020502A2 (en) * 2012-07-31 2014-02-06 Novartis Ag Markers associated with human double minute 2 inhibitors
WO2014065760A1 (en) * 2012-10-25 2014-05-01 Agency For Science, Technology And Research Methods for determining resistance against molecules targeting proteins
CN105378112B (zh) * 2013-07-03 2020-10-13 豪夫迈·罗氏有限公司 用于将用MDM2拮抗剂进行患者癌症治疗个人化的基于mRNA的基因表达

Similar Documents

Publication Publication Date Title
JP2017532959A5 (show.php)
Westphal et al. Circulating biomarkers for gliomas
Carini et al. Chromosome conformation signatures define predictive markers of inadequate response to methotrexate in early rheumatoid arthritis
Arimappamagan et al. A fourteen gene GBM prognostic signature identifies association of immune response pathway and mesenchymal subtype with high risk group
JP2010518811A5 (show.php)
Anaka et al. Intratumoral genetic heterogeneity in metastatic melanoma is accompanied by variation in malignant behaviors
Yuan et al. Identification of a Nine Immune‐Related lncRNA Signature as a Novel Diagnostic Biomarker for Hepatocellular Carcinoma
Liu et al. A single-cell transcriptional landscape of immune cells shows disease-specific changes of T cell and macrophage populations in human achalasia
Yu et al. Genome-wide analysis of genetic variations assisted by Ingenuity Pathway Analysis to comprehensively investigate potential genetic targets associated with the progression of hepatocellular carcinoma
Zhang et al. Identification of PANoptosis-relevant subgroups to evaluate the prognosis and immune landscape of patients with liver hepatocellular carcinoma
Xie et al. An 8‑gene signature predicts the prognosis of cervical cancer following radiotherapy
JP2022522354A (ja) 肝がん再発予測用dnaメチル化マーカー及びその用途
Cruz‐Granados et al. Multiomic‐based immune response profiling in migraine, vestibular migraine and Meniere's disease
Qu et al. Comprehensive analysis of the correlation between pyroptosis-related LncRNAs and tumor microenvironment, prognosis, and immune infiltration in hepatocellular carcinoma
Niu et al. Integrative Disulfidptosis‐Based Risk Assessment for Prognostic Stratification and Immune Profiling in Glioma
Wei et al. Identification and validation of IFI44 as a novel biomarker for primary Sjögren’s syndrome
Lu et al. Dysregulation of TFDP1 and of the cell cycle pathway in high-grade glioblastoma multiforme: a bioinformatic analysis
Cho et al. Involvement of DDX6 gene in radio-and chemoresistance in glioblastoma
CN113736879A (zh) 用于小细胞肺癌患者预后的系统及其应用
WO2021249355A1 (zh) 用于选择化疗响应患者组的生物标志物和方法及其用途
Yang et al. Construction of cuproptosis‑associated prognostic signature in colon adenocarcinoma based on bioinformatics and RT‑qPCR analysis
van Persie et al. Complete genome sequence of a novel chimpanzee polyomavirus from a western common chimpanzee
Pan et al. Identification of Cbx6 as a potential biomarker in renal ischemia/reperfusion injury
Wen et al. Prognostic value of PRR11 and immune cell infiltration in Ewing sarcoma
Chen et al. The correlation of miRNA expression and tumor mutational burden in uterine corpus endometrial carcinoma.